A61K 31/4439, A61K 31/14, A61K 31/13
A method of treating severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), otherwise known as COVID-19, infection by administering nicotinic receptor antagonists and/or PPAR-Î³ agonists is presented. A combination of mecamylamine, or an isomer thereof, and pioglitazone synergistically reduces replication of SARS-CoV-2 in virus-infected cells and also synergistically reduces inflammatory cytokines such as IL-6, IL-Î², and TNFÎ±, which have been associated with SARS-CoV-2 infection.
Sanberg, Paul Ronald; Brechot, Christian Bernard; Mohapatra, Shyam S.; and Mohapatra, Subhra, "Nicotinic receptor antagonists and pioglitazone as therapeutic agents for Covid-19" (2023). USF Patents. 1357.
University of South Florida